Skip to main content

Table 1 Patient demographics and clinical characteristics a

From: Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks: a cross-sectional study

Variables

Observations (N= 25)

Females, n (%)

19 (76%)

Mean age ± SD, yr (IQR)

56.2 ± 14.9 (26 to 77)

Disease duration, yr

12.3 [4.0 to 14.1] (0.9; 42.7)

RF-positive, n (%)

21 (84%)

Anti-CCP-positive, n (%)

22 (88%)

Mean DAS-28-CRP score (0 to 10)

4.8 ± 1.3 [2.2 to 6.8]

CRP, mg/L

20.9 [4 to 30] (1; 117)

VAS global (scale 0 to 100)

62.5 [41 to 83]

Tender joint count, 28 joints

7.1 [4 to 9] (0; 25)

Swollen joint count, 28 joints

7.8 [4 to 9] (1; 21)

DMARD monotherapy

 

 MTX, n (%)

2 (8%)

 SZS, n (%)

3 (12%)

 LFU, n (%)

2 (8%)

DMARD combination treatment

 

 MTX + SZS, n (%)

4 (16%)

 MTX + SZS + HCQ, n (%)

3 (12%)

 Biologic DMARDs (%)

8 (32%)

 Prednisolone monotherapy, 5 mg/day

2 (8%)

 No DMARDs (%)

1 (4%)

  1. aCCP, Cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; HCQ, Hydroxychloroquine; LFU, Leflunomide; MCP, Metacarpophalangeal joint; MTX, Methotrexate; PIP, Proximal interphalangeal joint; RF, Rheumatoid factor; SD, Standard deviation; SZS, Sulphasalazine; VAS, Visual Analogue Scale. Values are median [Q1 to Q3], (min; max) or mean ± SD unless otherwise stated.